Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Aquestive Therapeutics, Inc.

< Previous 1 2 3 Next >
Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Broadens Patent Estate for Anaphylm™
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Participate in Citizens Life Sciences Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Participate in Two Upcoming Conferences in March
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.